Sintilimab

Names

[ CAS No. ]:
2072873-06-2

[ Name ]:
Sintilimab

Biological Activity

[Description]:

Sintilimab (IBI308) is a fully human IgG4 monoclonal antibody that binds to PD-1, thereby blocking the interaction of PD-1 with its ligands (PD-L1 and PL-L2) and consequently helping to restore the endogenous antitumour T-cell response. Sintilimab can be used for the research of classical Hodgkin's lymphoma, non-small cell lung cancer and oesophageal cancer[1].

[Related Catalog]:

Research Areas >> Cancer

Signaling Pathways >> Immunology/Inflammation >> PD-1/PD-L1

Research Areas >> Inflammation/Immunology

[References]

[1]. Sheridan M Hoy. Sintilimab: First Global Approval Drugs. 2019 Feb;79(3):341-346.

Chemical & Physical Properties

[ Storage condition ]:
2-8°C

Related Compounds

The content on this webpage is sourced from various professional data sources. If you have any questions or concerns regarding the content, please feel free to contact service1@chemsrc.com.